Here’s Why United Airlines Stock Is Falling

United Airlines Holdings Inc (NASDAQ: UAL) shares are trading lower by 1.74% to $53.62 Thursday afternoon. Shares of several airline stocks are experiencing weakness after Southwest Airlines reported mixed second-quarter results.

United Airlines Holdings Inc (NASDAQ:UAL) shares are trading lower by 1.74% to $53.62 Thursday afternoon. Shares of several airline stocks are experiencing weakness after Southwest Airlines reported mixed second-quarter results. The company also reported an increase in economic fuel costs and operating expenses.

What Happened With Southwest?

Southwest Airlines reported quarterly earnings of $1.09 per share, missing the analyst consensus estimate of $1.10 by 0.91%. This represents a 16.15% decrease compared to earnings of $1.30 per share from the same period last year.

The company reported quarterly sales of $7.04 billion, surpassing the analyst consensus estimate of $6.98 billion by 0.82%. This is a 4.59% increase over sales of $6.73 billion in the same period last year.

CEO Bob Jordan stated that while the company’s network is mostly restored, it still needs optimization. They are taking steps to align their network, fleet plans and staffing with the current business environment.

Although business revenues are recovering, they have not reached pre-pandemic levels. Consequently, they are making changes to their 2024 flight schedules to adapt to the post-pandemic shifts in customer travel patterns…Read More

According to data from Benzinga Pro, UAL has a 52-week high of $58.23 and a 52-week low of $31.58.

Total
0
Shares
Related Posts
Read More

This Cannabinoids-Focused Pharma Co. Sees 50% YoY Surge In Revenue In 2023, Trims Losses

Cannabinoids-focused pharmaceutical company MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced on Wednesday its financial results for the full year and three months ended Dec. 31, 2023. Net revenue grew to CA$33 million ($24.3 million), from CA$22.1 million in 2022, representing roughly a 50% year-over-year increase. "Over the years we have invested in our infrastructure as a high quality and high-capacity pharmaceutical grade manufacturer, allowing us to grow sales with new opportunities and markets, without additional investment into capital or resources," David Pidduck said. "We are proud of the work completed in 2023 and excited about the future of MediPharm Labs."

MEDIF

Read More

SELLAS Life Sciences Receives FDA Fast Track Designation For SLS009 For Treatment Of Relapsed/Refractory Acute Myeloid Leukemia And Provides Updated Data For Phase 2a Study Of SLS009 In Relapsed/Refractory Acute Myeloid Leukemia Patients

- Phase 2a Enrollment Completed in 45 mg Safety Cohort: Median Overall Survival (OS) Not Reached; 89% of Patients Alive with Significant Antileukemic Effect Observed in 87.5% of Evaluable Patients -- First Enrolled

SLS